Clinical trials: Stage IV, NSCLC
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
- Trial name
- VIRO-25 (NCT06463665)
- Testing
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
- Where
- 15 sites in United States
- Volunteers
- 142 people
- Sponsor
- Genelux Corporation
Unresectable Non-small Cell Lung Cancer (NSCLC)
Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC
A prospective, multicenter, Phase-IV clinical trial to assess safety of Durvalumab in Indian adult patients with locally advanced, unresectable non-small cell lung cancer (NSCLC)
- Trial name
- NCT04416633
- Testing
- Durvalumab
- Where
- 12 sites in India
- Volunteers
- 100 people
- Sponsor
- AstraZeneca
Solid Tumor, Non-Small Cell Lung Cancer Metastatic
Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK
This study is aimed to determine the maximum tolerated dose of ensartinib, an oral ALK inhibitor in Chinese patients with ALK-positive non-small cell lung cancer
- Trial name
- NCT02959619
- Testing
- Ensartinib
- Where
- China
- Volunteers
- 48 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Solid Neoplasm, Stage III Pancreatic Cancer
Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors
This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with…
- Conditions
- Solid Neoplasm, Stage III Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer
- Trial name
- NCT02897375
- Testing
- Carboplatin, Cisplatin, Palbociclib
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Emory University
Non-small Cell Lung Cancer Stage IV
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
The goal of this clinical trial is to confirm that SB27 works in the same way as Keytruda in metastatic non-squamous non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT06348199
- Testing
- SB27, Keytruda
- Where
- 93 sites in Bosnia and Herzegovina, Brazil and 12 more
- Volunteers
- 555 people
- Sponsor
- Samsung Bioepis Co., Ltd.
Lung Cancer, Non-Small Cell
A Single-Arm, Phase Ⅰb Study of Golidocitinib Combined With Anti-PD-1 for the Treatment of Previously Treated NSCLC
This study is a phase Ib, single-center, single-arm exploratory clinical study designed to evaluate the safety and efficacy of Golidocitinib in combination with anti-PD-1 monoclonal antibody in locally advanced or metastatic…
- Trial name
- NCT06690671
- Testing
- Golidocitinib in combination with anti-PD-1
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shanghai Chest Hospital
Lung Cancer
Photodynamic Therapy Using HPPH in Treating Patients With Advanced Non-Small Cell Lung Cancer That Blocks the Air Passages
RATIONALE: Photodynamic therapy uses a drug, such as HPPH, that becomes active when it is exposed to a certain kind of light. When the drug is active, tumor cells are killed.
- Trial name
- NCT00528775
- Testing
- HPPH, endoscopic procedure
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Roswell Park Cancer Institute
Non-small Cell Lung Cancer Metastatic
Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients
This is a phase IV multicenter trial to evaluate the pharmacoeconomic (PE) impact of crizotinib and its companion diagnostic test used in a real-life setting in advanced ALK-positive non-small cell lung cancer (NSCLC) patients.
- Trial name
- NCT02228421
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- PeriPharm
Metastatic Non Small Cell Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma
MOv19-BBz CAR T Cells in FRa+ Cancers
This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells in patients with FRa+ cancers.
- Trial name
- NCT07116057
- Testing
- MOv19-BBz CAR T cells, Cyclophosphamide/Fludarabine, FRa Expression Testing
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Lung Cancer
3-AP and Gemcitabine in Treating Patients With Metastatic Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy such as gemcitabine use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00064064
- Testing
- gemcitabine hydrochloride, triapine
- Where
- 5 sites in United States, Netherlands
- Sponsor
- Vion Pharmaceuticals
Lung Cancer
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well…
- Trial name
- NCT00534209
- Testing
- Allogeneic B7.1/HLA-A1
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC
- Conditions
- Non-small Cell Lung Cancer Stage III, Non-Small-Cell Lung Cancer Metastatic, Adenocarcinoma of Lung, EGFR Wildtype
- Trial name
- NCT02946216
- Testing
- ctDNA analysis
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First People's Hospital of Hangzhou
Non Small Cell Lung Cancer
Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer
The purpose of this clinical trial is to find out whether or not the combination of NOV-002 with chemotherapy (paclitaxel and carboplatin) is better at improving overall survival time when compared to chemotherapy alone in people…
- Trial name
- NCT00347412
- Testing
- Paclitaxel, NOV-002, Carboplatin
- Where
- 75 sites in United States, Canada and 10 more
- Volunteers
- 903 people
- Sponsor
- Cellectar Biosciences, Inc.
Lung Cancer Non-small Cell Stage IV, Squamous Cell Lung Cancer
A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer
This is a phase III, randomized, double-blinded, multicenter clinical study to evaluate the efficiency and safety of AK105 (Anti-PD1 antibody) plus paclitaxel and carboplatin vs placebo plus paclitaxel and carboplatin as…
- Trial name
- NCT03866993
- Testing
- AK105, Paclitaxel, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 350 people
- Sponsor
- Akeso
Lung Cancer
Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for non-small cell lung cancer.
- Trial name
- NCT00004100
- Testing
- cisplatin, gemcitabine hydrochloride, vinorelbine tartrate
- Where
- 29 sites in Italy
- Sponsor
- Istituto Nazionale per lo Studio e la Cura dei Tumori
NSCLC
IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC
The purpose of this study is to determine if IO102 combined with pembrolizumab with or without chemotherapy is safe tolerable and effective in the treatment of Non-small Cell Lung Carcinoma (NSCLC).
- Trial name
- NCT03562871
- Testing
- IO102, pembrolizumab (Keytruda), Carboplatin (Carboplatin Kabi)
- Where
- 13 sites in Germany, Netherlands and 2 more
- Volunteers
- 109 people
- Sponsor
- IO Biotech
Oncology, NSCLC Stage IV
Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer
A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer.
- Conditions
- Oncology, NSCLC Stage IV, NSCLC, Stage III
- Trial name
- LUNGVAC (NCT05344209)
- Testing
- UV1, Sagramostim, Anti-PD-1/PD-L1 treatment
- Where
- Norway
- Volunteers
- 138 people
- Sponsor
- Vestre Viken Hospital Trust
Lung Cancer
Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy, such as vinorelbine, gemcitabine, docetaxel, paclitaxel, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00079287
- Testing
- carboplatin, docetaxel, gemcitabine hydrochloride
- Where
- 24 sites in Japan
- Sponsor
- Japan Multinational Trial Organization
Metastatic Non-small Cell Lung Cancer
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients…
- Trial name
- LUNAR-2 (NCT06216301)
- Testing
- NovoTTF-200T, Pembrolizumab, Platinum based chemotherapy
- Where
- 104 sites in United States, Austria and 15 more
- Volunteers
- 734 people
- Sponsor
- NovoCure GmbH
Non-Small Cell Lung Cancer
A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer
This randomized, Phase III, double-blind, placebo-controlled study will evaluate the safety and efficacy of MetMAb (onartuzumab) in combination with Tarceva (erlotinib) compared with treatment with Tarceva alone in patients with…
- Trial name
- NCT02031744
- Testing
- erlotinib [Tarceva], Onartuzumab [MetMAb]
- Where
- 8 sites in China
- Volunteers
- 530 people
- Sponsor
- Hoffmann-La Roche
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.